Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun’s Key Halol Plant Flunks FDA Inspection Again

Executive Summary

The US FDA has flagged more issues at Indian firm Sun Pharma’s largest manufacturing plant in Halol but analysts are hoping the infractions are minor and that the Indian facility will get the regulatory green light soon, ending a blacklist on the factory supplying new products to the US.
Advertisement

Related Content

Sun’s Halol Site Out Of Compliance Rut, Could Add Some SPARC Too
Big Launch Year Coming Up In US For Sun But Spends High Too
Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended
Aurobindo Injectables Unit Falls Foul Of FDA But Analysts Hopeful
Signs Of Improving FDA Inspection Outcomes At Indian Sites But Long Road Ahead
Sun Q3 Profits Dive, Halol Resolution Stays Pivotal To Trigger Reset
Sun Recruits Ex-Cipla Manufacturing Veteran In Compliance Push
Analysts Cut Sun Forecasts After New Halol Site Faults

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100471

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel